Clinical-stage biotechnology company developing targeted therapies for cancer. Our lead compound, gedatolisib, is a potential first-in-class PI3K-mTOR inhibitor
Joined August 2022
- Tweets 114
- Following 83
- Followers 237
- Likes 0
105 Photos and videos
Listen in tomorrow morning as Celcuity CEO and co-founder Brian Sullivan participates in a fireside chat presentation with equity research analyst Rich Law the at Goldman Sachs 47th Annual Global Healthcare Conference in Miami. Webcast link: bit.ly/4usxnwH
$CELC
4
8
426
Celcuity CEO Brian Sullivan will participate in a fireside chat with Equity Research Analyst Maury Raycroft at the Jefferies Global Healthcare Conference. Listen in: bit.ly/4uRNdlz
$CELC #JefferiesHealthcare
3
6
387
Celcuity reported detailed results for the PIK3CA mutant cohort of the pivotal Phase 3 VIKTORIA-1 trial in patients with HR /HER2- advanced breast cancer. Read our press release here: bit.ly/4vrUSa8
9
19
1,548
$CELC announced that we will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026, at 8:00 a.m. EDT. bit.ly/49toVps
1
23
6,600
We look forward to attending the upcoming conferences in June: Jefferies Global Healthcare Conference in New York and Goldman Sachs 47th Annual Global Healthcare Conference 2026.
For more information: bit.ly/42WbmL
$CELC
2
6
402
$CELC reports financial results for Q1 2026 and provides a corporate update today. Press release: bit.ly/4npRb1G | Webcast at 4:30 pm ET: bit.ly/43ajaZY
2
3
291
$CELC announces updates to our clinical development plan including expansion of our Phase 3 VIKTORIA-2 clinical trial to include a second study evaluating gedatolisib as 1L treatment in patients with endocrine-sensitive HR /HER2- advanced breast cancer. bit.ly/3P5iWQG
8
18
1,271
$CELC will report on Q1 2026 financial results next Thursday, May 14, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: bit.ly/4uASQUF
2
211
Today, we announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patients with HR /HER2- PIK3CA mutant advanced breast cancer. bit.ly/4tKpBP0
5
12
340
Celcuity reports financial results for the fourth quarter and full year 2025 and provides corporate update: bit.ly/4bHFzSk
Listen in to our webcast conference call today at 4:30 pm ET: bit.ly/4lNVOSu
$CELC
2
3
327
$CELC will report on Q4 and full year 2025 financial results next Wednesday, March 25, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: bit.ly/4uTNu87
2
216
Results from the Phase 3 VIKTORIA-1 trial were published in @JCO_ASCO. We would like to thank Dr. Sara Hurvitz for serving as a co-primary investigator and for helping us potentially bring this important therapy to patients. Read the manuscript: bit.ly/4uCIx3p
1
2
275
We are proud to announce publication in the Journal of Clinical Oncology of results from the Phase 3 VIKTORIA-1 clinical trial. Read more here: bit.ly/4ujOzWn $CELC #gedatolisib
3
6
270
Tune in tomorrow to listen to our fireside chat at the Leerink Global Healthcare Conference: bit.ly/4c6WAqY
$CELC
3
131
Tune in tomorrow to listen to our fireside chat at the TD Cowen 46th Annual Health Care Conference: bit.ly/4qOFgKZ
4
124
We look forward to attending the upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and the 2026 Jefferies Biotech on the Beach Summit. For more information: bit.ly/4cf7mvs
$CELC
3
5
378
We are pleased to announce the appointment of Chip Romp to Celcuity’s Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to $CELC, with an emphasis on leading commercial organizations in the oncology setting. bit.ly/4rSQPlw
2
4
411
Tune in tomorrow and listen to our fireside chat with Celcuity CEO, Brian Sullivan, and biotech research analyst, Brad Canino, at the Guggenheim Emerging Outlook: Biotech Summit 2026. Listen to the webcast: bit.ly/3NRO2dr
1
3
222
$CELC is participating in a fireside chat and hosting investor meetings at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. Read more here: bit.ly/45QFxFM
2
2
341
$CELC is proud to announce the acceptance of our NDA for gedatolisib in HR /HER2-/PIK3CA wild-type advanced breast cancer. Read more here: bit.ly/4sQ5sqI
4
10
1,377